ABBV - ABBVIE INC. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
ABBVIE INC.
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
IPO Date: December 14, 2012
Sector: Healthcare
Industry: Drug Manufacturers
Market Cap: $481.4B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.24 | 1.13%
Avg Daily Range (30 D): $1.94 | 0.75%
Avg Daily Range (90 D): $2.97 | 1.21%
Institutional Daily Volume
Avg Daily Volume: 6.07M
Avg Daily Volume (30 D): 2.86M
Avg Daily Volume (90 D): 3.94M
Trade Size
Avg Trade Size (Sh.): 100
Avg Trade Size (Sh.) (30 D): 43
Avg Trade Size (Sh.) (90 D): 50
Institutional Trades
Total Institutional Trades: 67,122
Avg Institutional Trade: $11.27M
Avg Institutional Trade (30 D): $35.23M
Avg Institutional Trade (90 D): $37.17M
Avg Institutional Trade Volume: .1M
Avg Institutional Trades (Per Day): 19
Market Closing Trades
Avg Closing Trade: $99.05M
Avg Closing Trade (30 D): $271.01M
Avg Closing Trade (90 D): $326.45M
Avg Closing Volume: 802.44K
 
News
Oct 9, 2026 @ 2:30 PM
A Stock Market Crash Is Coming By the End of 2027,...
Source: Prosper Junior Bakiny
Oct 8, 2026 @ 2:47 PM
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy...
Source: Na
Oct 7, 2026 @ 1:57 PM
Will Linzess Continue to Aid Ironwood's Top-Line G...
Source: Na
Oct 6, 2026 @ 2:22 PM
AbbVie's Epcoritamab Combo Shows PFS Benefit in Fr...
Source: Na
Oct 6, 2026 @ 11:23 AM
IYH Beats IXJ on Returns While Global Fund Offers ...
Source: Sarah Sidlow
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $3.54 $2.04 $.39
Diluted EPS $3.54 $2.03 $.39
Revenue $64.39B $16.99B $15B
Gross Profit $46.02B $12.7B $10.78B
Net Income / Loss $6.32B $3.62B $697M
Operating Income / Loss $16.87B $6.43B $3.99B
Cost of Revenue $18.37B $4.29B $4.22B
Net Cash Flow $102M $-2822M $4.16B
PE Ratio